Physician

Binit Prabhulal Shah, M.D.

According to 2025 Medicare claims, Binit Shah, M.D. (NPI: 1578726592) practices pain management in the Charlotte-Concord-Gastonia, NC-SC market, with the plurality of this provider's patient population coming from Mecklenburg, NC. This provider's primary affiliated billing organization is CAROLINAS PAIN CENTER PLLC (NPI: 1912292335; TIN: 452521861) and primary practice location at 28078-9120.

Shah's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 624 traditional Medicare patients, billed 4,443 HCPCS/CPT codes, and received $519,327 in Medicare payments. The top billing code was G0481 (Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms). Part D data shows 1,011 prescription claims across 295 beneficiaries totaling $96,733 in drug costs, led by Aimovig Autoinjector (Erenumab-Aooe). 2020 DME data shows 24 claims. Open Payments data shows 84 records totaling $19,895. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs started with an early spike, then settled into a lower baseline, moving from $265,832 to $96,733. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	533	6,436	$383,941
2016	524	7,004	$266,331
2017	530	6,361	$253,002
2018	604	7,525	$310,522
2019	595	6,841	$376,620
2020	558	7,560	$369,253
2021	542	6,411	$378,259
2022	587	3,313	$305,689
2023	613	3,815	$375,972
2024	624	4,443	$519,327

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	466	2,241	$265,832
2016	493	3,031	$385,884
2017	441	2,023	$235,542
2018	459	2,276	$269,060
2019	317	1,217	$110,333
2020	402	1,728	$106,848
2021	393	1,963	$118,885
2022	354	1,304	$123,404
2023	258	967	$132,965
2024	295	1,011	$96,733

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	35	$604
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	18	$155
2020	N/R	24	$2,291
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms	421	603	$152
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	162	162	$128
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	473	1,784	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	98	122	$69
80307	Testing for presence of drug, by chemistry analyzers	524	886	$59

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Aimovig Autoinjector	Erenumab-Aooe	12	470	$11,374
Fentanyl	Fentanyl	30	855	$3,764
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	96	2,742	$3,160
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	106	2,648	$2,343
Naloxone Hcl	Naloxone Hcl	29	160	$2,040

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	75	$4,574	Saluda Medical Americas, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	9	$15,321	GlaxoSmithKline, LLC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Binit Prabhulal Shah, M.D.?

Tedicare shows public-source Medicare data for Binit Prabhulal Shah, M.D. (NPI 1578726592), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Binit Prabhulal Shah, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Binit Prabhulal Shah, M.D.?

Binit Prabhulal Shah, M.D. is linked to CAROLINAS PAIN CENTER PLLC (billing NPI 1912292335) in the available physician profile data.

Does Binit Prabhulal Shah, M.D. have Open Payments data?

Binit Prabhulal Shah, M.D. has 84 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.